Takeda Pharmaceutical Company (TAK)
NYSE:TAK
Want to see TAK full AI Analyst Report?
Total Valuation
Takeda Pharmaceutical Company has a market cap or net worth of $52.43B. The enterprise value is $12.60T.
Market Cap$52.43B
Enterprise Value$12.60T
Share Statistics
Takeda Pharmaceutical Company has 3,182,525,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,182,525,000
Owned by Insiders0.10%
Owned by Institutions1.19%
Financial Efficiency
Takeda Pharmaceutical Company’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 3.11%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.01
Return on Invested Capital (ROIC)3.11%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee96.94M
Profits Per Employee4.13M
Employee Count49,281
Asset Turnover0.31
Inventory Turnover1.67
Valuation Ratios
The current PE Ratio of Takeda Pharmaceutical Company is ―. Takeda Pharmaceutical Company’s PEG ratio is 0.52.
PE Ratio―
PS Ratio1.94
PB Ratio1.19
Price to Fair Value1.19
Price to FCF11.45
Price to Operating Cash Flow8.46
PEG Ratio0.52
Income Statement
In the last 12 months, Takeda Pharmaceutical Company had revenue of 4.78T and earned 203.33B in profits. Earnings per share was 63.91.
Revenue4.78T
Gross Profit2.44T
Operating Income573.04B
Pretax Income275.88B
Net Income203.33B
EBITDA1.34T
Earnings Per Share (EPS)63.91
Cash Flow
In the last 12 months, operating cash flow was 973.34B and capital expenditures -216.13B, giving a free cash flow of 757.21B billion.
Operating Cash Flow973.34B
Free Cash Flow757.21B
Free Cash Flow per Share237.93
Dividends & Yields
Takeda Pharmaceutical Company pays an annual dividend of $0.321, resulting in a dividend yield of 3.86%
Dividend Per Share$0.321
Dividend Yield3.86%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.05
52-Week Price Change16.48%
50-Day Moving Average17.44
200-Day Moving Average15.92
Relative Strength Index (RSI)44.16
Average Volume (3m)3.08M
Important Dates
Takeda Pharmaceutical Company upcoming earnings date is Jul 30, 2026, Before Open (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Takeda Pharmaceutical Company as a current ratio of 1.27, with Debt / Equity ratio of 62.80%
Current Ratio1.27
Quick Ratio0.70
Debt to Market Cap0.53
Net Debt to EBITDA3.22
Interest Coverage Ratio1.51
Taxes
In the past 12 months, Takeda Pharmaceutical Company has paid 72.27B in taxes.
Income Tax72.27B
Effective Tax Rate0.26
Enterprise Valuation
Takeda Pharmaceutical Company EV to EBITDA ratio is 10.14, with an EV/FCF ratio of 16.77.
EV to Sales2.84
EV to EBITDA10.14
EV to Free Cash Flow16.77
EV to Operating Cash Flow13.63
Balance Sheet
Takeda Pharmaceutical Company has $597.63B in cash and marketable securities with $4.90T in debt, giving a net cash position of -$4.31T billion.
Cash & Marketable Securities$597.63B
Total Debt$4.90T
Net Cash-$4.31T
Net Cash Per Share-$1.35K
Tangible Book Value Per Share-$463.43
Margins
Gross margin is 58.76%, with operating margin of 11.99%, and net profit margin of 4.26%.
Gross Margin58.76%
Operating Margin11.99%
Pretax Margin5.77%
Net Profit Margin4.26%
EBITDA Margin28.00%
EBIT Margin11.99%
Analyst Forecast
The average price target for Takeda Pharmaceutical Company is $21.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$21.00
Price Target Upside49.15% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-0.47%
EPS Growth Forecast83.79%